Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fiona R Fernando
Observed names:
F Fernando,
F. Fernando,
Fernando, Fiona,
Fiona Fernando
Institutions:
Imperial College Healthcare NHS Trust,
Hammersmith Hospital,
Imperial College London
Observed institutions:
Imperial College Healthcare NHS Trust,
Queen Mary University of London,
Hammersmith Hospital,
St Mary's Hospital,
Barts Cancer Institute,
Imperial College London
show all 6
ORCID:
0000-0002-7031-5054
Observed ORCID:
0000-0002-7031-5054
OpenAlex ID:
A5110508169
Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality
2017
·
A J Innes
, B H Mullish
, et al.
·
Bone Marrow Transplantation
·
35
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
2024
·
Simone Claudiani
, Farhan Chughtai
, et al.
·
Leukemia
·
30
PDF
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score
2024
·
Fiona Fernando
, Maria Sol Andres
, et al.
·
Cardio-Oncology
·
25
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
2024
·
Andrew J. Innes
, Chloe Hayden
, et al.
·
Leukemia
·
18
PDF
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia
2024
·
George Nesr
, Simone Claudiani
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
17
P706: Asciminib Use in Cml: the Uk Experience
2022
·
A. Innes
, V. Orovboni
, et al.
·
HemaSphere
·
12
Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality
2019
·
Andrew J. Innes
, Philippa Woolley
, et al.
·
Leukemia
·
12
Real-World Experience of Asciminib: Factors Associated with Response
2022
·
Andrew J. Innes
, Chloe Hayden
, et al.
·
Blood
·
11
How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia
2021
·
Fiona Fernando
, Harry Frederick Robertson
, et al.
·
Clinical Hematology International
·
10
PDF
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
2026
·
Prithviraj Bose
, Haris Ali
, et al.
·
Journal of Clinical Oncology
·
9
Introducing a prognostic score for successful treatment‐free remission in chronic myeloid leukaemia
2026
·
Simone Claudiani
, Silvia Metelli
, et al.
·
British Journal of Haematology
·
7
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia
2023
·
Fiona Fernando
, Andrew J. Innes
, et al.
·
Bone Marrow Transplantation
·
7
PDF
Treatment‐free remission in CML patients with additional chromosome abnormalities in the Philadelphia‐positive clone or variant Philadelphia translocations
2024
·
Simone Claudiani
, Lynette Chee
, et al.
·
American Journal of Hematology
·
6
PDF
A novel mutation in exon 2 of FGB caused by c.221G>T † substitution, predicting the replacement of the native Arginine at position 74 with a Leucine (p.Arg74Leu † ) in a proband from a Kurdish family with dysfibrinogenaemia and familial venous and arterial thrombosis
2016
·
Abdul A. Shlebak
, Alexia D. Katsarou
, et al.
·
Journal of Thrombosis and Thrombolysis
·
5
PDF
Molecular basis of acute lymphoblastic leukemia
2019
·
Bela Patel
, Fiona Fernando
·
Wiley eBooks
·
2
Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia
2025
·
Fiona Fernando
, Claudia Wasko
, et al.
·
eJHaem
·
1
PDF
Incidence, Interpretation and Management of Liver Function Abnormalities in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI)
2023
·
Harry F Robertson
, Victoria Orovboni
, et al.
·
Blood
·
1
PDF
Treatment‐free remission in CML patients with prior TKI failure is not influenced by previous BCR::ABL1 kinase domain mutations
2026
·
Simone Claudiani
, Silvia Metelli
, et al.
·
British Journal of Haematology
PDF
Changes in disease responses after discontinution of tyrosine kinase inhibitors (TKI) for pregnancy in established chronic myeloid leukaemia (CML): Evidence for the basis of advice for women of child-bearing age
2025
·
Jenny Chan
, Harry Robertson
, et al.
·
Blood
PDF
BCR::ABL1 transcript Type Does Not Impact Allogeneic Stem Cell Transplant Outcome in Chronic Myeloid Leukaemia
2024
·
Isidora Staikdou
, Simone Claudiani
, et al.
·
Blood
Cardiovascular events in CML patients treated with nilotinib: validation of the HFA-ICOS baseline risk score
2024
·
M Andres
, F Fernando
, et al.
·
European Heart Journal
Allogeneic Hematopoietic Cell Transplantation in CML: When and How?
2023
·
Fiona Fernando
, Andrew J. Innes
·
Springer eBooks
P713: Real-world Management of Patients With Chronic Myeloid Leukaemia (cml): First Analysis From the Uk National Registry for Cml
2022
·
G. Nesr
, R. Szydlo
, et al.
·
HemaSphere
S1626 Incomplete Count Recovery in Patients With Complete Remission Prior to Allogeneic Hct for Aml Is Associated With a High Non‐relapse Mortality Without an Increased Relapse Risk
2019
·
A. Innes
, P. Wooley
, et al.
·
HemaSphere
Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk
2018
·
Andrew James Innes
, Philippa Woolley
, et al.
·
Blood
Show more works
View as search
Works count:
28
Citation count:
208
H-index:
9
I10-index:
9
Year
Topic
Type